poisar

Stocks · News reference

X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor

Fiscal.ai

During its 2026 Virtual Investor Day, X4 Pharmaceuticals provided updates on its clinical programs, including the expected completion of 4WARD trial enrollment and market projections for mavorixafor in primary chronic neutropenia.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading